Eurofins Discovery Extends AI-powered Integrated Drug Discovery Collaboration
October 10 2024 - 11:15AM
Business Wire
2nd Year Alliance with Dompé farmaceutici S.p.A.
Eurofins Discovery, an industry-leading provider of products and
services for drug discovery research, announced today the renewal
of its collaboration with Italy-based Dompé farmaceutici S.p.A.,
which is applying their internal AI platform to accelerate the
identification of novel therapeutics.
This collaboration moves into a second year as a result of the
combined strengths of Eurofins Discovery’s DiscoveryOne™
comprehensive Integrated Drug Discovery capabilities with Dompé’s
powerful supercomputing AI platform. The combined strengths of
Eurofins Discovery’s capabilities and Dompé’s AI Platform is an
effective example of how Eurofins Discovery can progress drug
discovery for companies that are utilizing internal AI platforms.
Eurofins Discovery’s Integrated Drug Discovery applies its
capabilities in optimized, target-specific screening cascades,
automated chemical synthesis, and high-quality data generation.
Eurofins Discovery has proven expertise in tackling novel
biology, with a portfolio of over 12,000 off-the-shelf assays, and
extensive experience in areas such as protein production,
high-throughput screening (HTS), custom assay design, biophysics,
translational biology, ADME, pharmacokinetics and synthetic and
automated chemistry. An essential part of the collaboration is
Eurofins Discovery’s drug discovery expertise, which is
instrumental in the design and execution of each project, while
ensuring efficient progress across this multi-target program.
Dompé brings its Exscalate supercomputing and AI data analytics
into a virtual screening platform with the power to evaluate
trillions of molecules for each novel target. Eurofins Discovery is
optimally positioned to support Dompé’s approach to discovery, and
researchers in similar pursuits of novel molecules, to accelerate
research that will ultimately improve human health.
About Eurofins Discovery Eurofins Discovery supports drug
discovery research with over 23,000 products and services developed
in 40+ years of industry leadership. Benefit from the strength of
our solutions that revolutionize your drug discovery.
About Dompé farmaceutici
Dompé is a privately owned biopharmaceutical company with 130
years of history and expertise in life sciences. Headquartered in
Milan, the company also has operations in Boston, and San
Francisco. It conducts research activities as part of a network of
leading global research centres and universities. Dompé uses a
variety of next generation proprietary chemo and bioinformatic
tools, including the Exscalate platform, one of the most powerful
and cost-efficient intelligent supercomputing drug discovery
platforms in the world.
www.dompe.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241010180689/en/
Media:
Aida Yodites, Director, Marketing Communications
aida.yodites@discovery.eurofinsus.com
Enerplus (TSX:ERF)
Historical Stock Chart
From Nov 2024 to Dec 2024
Enerplus (TSX:ERF)
Historical Stock Chart
From Dec 2023 to Dec 2024
